INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
Portfolio Pulse from
Pomerantz LLP has filed a class action lawsuit against Intellia Therapeutics (NTLA) regarding potential securities fraud. The lawsuit stems from the company's January 9, 2025 announcement of strategic changes, including discontinuing NTLA-3001 drug development, cutting 27% of workforce, and the retirement of its Chief Scientific Officer. The stock price dropped 15.14% following this news.
March 27, 2025 | 10:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Potential securities fraud lawsuit filed following significant corporate strategy changes and workforce reduction
The class action lawsuit, combined with significant corporate restructuring and workforce reduction, suggests potential negative short-term market sentiment for Intellia Therapeutics
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100